Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

HIV/AIDS infected children can now benefit from a European and Developing Countries Clinical Trials Partnership funded trial

17.09.2007
In August, the United States (US) Federal Drug Administration (FDA) gave a tentative approval to a fixed-dose anti-HIV drug specifically formulated for paediatric use. The fixed-dose combination scored tablet of lamivudine 30mg, stavudine 6mg and nevirapine 50mg (Triomune Baby) and double this strength (Triomune Junior) is manufactured by CIPLA pharmaceuticals.

It is administered twice daily, according to a simple weight-based table, allowing for easy prescribing. It can also be ‘snapped in half’ and dissolved in water for young children who cannot swallow tablets. As a result of this tentative approval, this FDC antiretroviral drug will be included in the World Health Organisation (WHO) Prequalification Programme and will become available for distribution under the Presidents Emergency Plan for AIDS relief (PEPFAR) and Clinton Foundation programmes.

EDCTP, the funder of the pharmacokinetic study leading to this tentative approval, congratulates Professor Chifumbe Chintu from the School of Medicine and Department of Paediatrics, University Teaching Hospital, Lusaka and his Zambian team, along with research collaborators from the Netherlands and the Medical Research Council (MRC) Clinical Trials Unit, United Kingdom on their work. Triomune Baby and Junior have already been approved in Zambia and are currently being used to treat children there.

Treatment of HIV/AIDS in children is a great challenge in resource-constrained settings. One of the reasons for this is the difficulty and cost of giving paediatric formulations, particularly syrups, of anti-HIV drugs to children. The absence of appropriate paediatric formulations often necessitates administering divided adult tablets to HIV-infected children. This can lead to incorrect dosing, especially under dosing, and increases the risk of the rapid development of resistance to the drugs. The problem is compounded by underlying malnutrition in these children, and the lack of knowledge about how malnutrition affects drug levels in the body.

The pharmacokinetic study undertaken by Professor Chintu and colleagues is part of a larger ongoing randomised trial that is evaluating the necessity of lead-in treatment for one of the anti-HIV drugs (nevirapine) in the triple combination pill. Data generated from the pharmacokinetic (dosing) study were included in the submission for registration and contributed to the US FDA granting tentative approval for the registration of this drug for use in children. This will be the first FDC drug specifically designed for young children to be registered by the FDA.

Triomune Baby and Junior tablets are scored, crushable and water soluble for children who cannot swallow tablets. The fact that all three drugs are combined in one tablet (which is layered to ensure equal distribution of drugs if snapped in half), and that tablets can be stored, distributed, and administered easily to children represents a significant advance in HIV treatment for children in resource-limited settings. The tentative FDA registration paves the way for the drug to receive WHO prequalification status. Additionally, it will allow programmes such as PEPFAR and the Clinton Foundation, which make antiretroviral drugs available in many resource-constrained countries, to purchase the drug for widespread use in HIV-infected children.

Commenting on this achievement Professor Charles Mgone, the Executive Director of EDCTP said, “This is a great achievement which underpins the primary goal of EDCTP of accelerating new or improved interventions against diseases of poverty through north-south collaboration.”

Professor Chifumbe Chintu thanks EDCTP for funding the trial and offering much needed assistance during the still ongoing study. He sends his special gratitude to colleagues: Professor Diane Gibb and her team at MRC Clinical Trials Unit, London; Dr David Burger and his colleagues at Radboud University Medical Centre, Nijmegen, The Netherlands; Dr David Bangsberg and colleagues at the Epidemiology and Prevention Intervention Centre, San Francisco General Hospital and in particular, to the team at the CHAPAS Clinic Lusaka, Zambia. Special thanks go to CIPLA pharmaceuticals for providing the Triomune Baby and Junior tablets for the study.

Tentative approval

An FDA tentative approval is based on the FDA opinion that the product meets all of manufacturing quality and clinical safety and efficacy requirements. Although existing patents and/or marketing exclusivity prevent the approval of the product in the United States, the product can be used for the treatment of AIDS patients abroad.

World Health Organisation Prequalification Programme

This is a program many countries with developing economies use to guide their purchasing of drug products from specific manufacturers so they can be assured they are purchasing quality medicinal products.

Ilona van den Brink | alfa
Further information:
http://www.edctp.org/Press_Releases.292.0.html
http://www.fda.gov/bbs/topics/NEWS/2007/NEW01681.html

More articles from Health and Medicine:

nachricht Penn vet research identifies new target for taming Ebola
12.01.2017 | University of Pennsylvania

nachricht The strange double life of Dab2
10.01.2017 | University of Miami Miller School of Medicine

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

Im Focus: How to inflate a hardened concrete shell with a weight of 80 t

At TU Wien, an alternative for resource intensive formwork for the construction of concrete domes was developed. It is now used in a test dome for the Austrian Federal Railways Infrastructure (ÖBB Infrastruktur).

Concrete shells are efficient structures, but not very resource efficient. The formwork for the construction of concrete domes alone requires a high amount of...

Im Focus: Bacterial Pac Man molecule snaps at sugar

Many pathogens use certain sugar compounds from their host to help conceal themselves against the immune system. Scientists at the University of Bonn have now, in cooperation with researchers at the University of York in the United Kingdom, analyzed the dynamics of a bacterial molecule that is involved in this process. They demonstrate that the protein grabs onto the sugar molecule with a Pac Man-like chewing motion and holds it until it can be used. Their results could help design therapeutics that could make the protein poorer at grabbing and holding and hence compromise the pathogen in the host. The study has now been published in “Biophysical Journal”.

The cells of the mouth, nose and intestinal mucosa produce large quantities of a chemical called sialic acid. Many bacteria possess a special transport system...

Im Focus: Newly proposed reference datasets improve weather satellite data quality

UMD, NOAA collaboration demonstrates suitability of in-orbit datasets for weather satellite calibration

"Traffic and weather, together on the hour!" blasts your local radio station, while your smartphone knows the weather halfway across the world. A network of...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

Nothing will happen without batteries making it happen!

05.01.2017 | Event News

 
Latest News

Water - as the underlying driver of the Earth’s carbon cycle

17.01.2017 | Earth Sciences

Satellite-based Laser Measurement Technology against Climate Change

17.01.2017 | Machine Engineering

Studying fundamental particles in materials

17.01.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>